Ghaziabad Online

Hyperphosphatemia Market to Exhibit CAGR of 4.54% for the Study Period of 2018-2030, Backed by Expected Launch of Emerging Therapies, Reports DelveInsight

 Breaking News
  • No posts were found

Hyperphosphatemia Market to Exhibit CAGR of 4.54% for the Study Period of 2018-2030, Backed by Expected Launch of Emerging Therapies, Reports DelveInsight

May 20
02:21 2021
Hyperphosphatemia Market to Exhibit CAGR of 4.54% for the Study Period of 2018-2030, Backed by Expected Launch of Emerging Therapies, Reports DelveInsight

Hyperphosphatemia Market

Hyperphosphatemia is a condition characterized by an increase in serum phosphate level above 4.5 mg/100 mL. The condition usually occurs due to a decrement in renal function, commonly among chronic kidney disease (CKD) patients, in which phosphate levels shoot up abnormally high. The condition may result from varying factors like an increase in phosphate intake, a decrease in phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space; the health of kidneys plays a crucial role as it is the kidneys that control the amount of phosphate in the blood.

DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China and Taiwan.

 

Some facts of Hyperphosphatemia Market Report are:

  • In the year 2020, the total diagnosed prevalent cases of CKD were 27,063,599 in the 7MM, China and Taiwan.
  • In the United States, the patients with Stage 3–5 CKD accounted for 2,317,671 in 2020.
  • In 2020, in the United States, the prevalence of ESRD was 797,101 and patients with ESRD on dialysis accounted for 565,941 cases.
  • The total prevalent population of hyperphosphatemia in the 7MM, China and Taiwan is expected to increase at a CAGR of 0.42% during the forecast period 2021–2030.
  • The United States, in 2020, accounted for 481,050 prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis. Among EU5 countries, Germany had the highest number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 55,631 in 2020. Whereas, Spain accounted for the least number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 23,847 in 2020.
  • China and Taiwan accounted for 487,163 and 73,208 prevalent cases of hyperphosphatemia in 2020.

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/hyperphosphatemia-market

 

Some of Hyperphosphatemia Companies are:

  • Shanghai Alebund Pharmaceuticals
  • Chugai Pharmaceuticals
  • Akebia Therapeutics
  • Vifor Fresenius Medical Care Renal Pharma
  • Astellas Pharma
  • Ardelyx
  • Shield Therapeutics
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/hyperphosphatemia-market

 

Scope of the Hyperphosphatemia Report

  • The report covers the descriptive overview of Hyperphosphatemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Hyperphosphatemia epidemiology and treatment in the 7MM, China and Taiwan.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hyperphosphatemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hyperphosphatemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM, China and Taiwan.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hyperphosphatemia market

 

Some of Hyperphosphatemia Therapies are:

  • Auryxia
  • Velphoro
  • Kiklin
  • Ibsrela (Tenapanor)
  • VS-505
  • EOS789
  • PT20
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/hyperphosphatemia-market

 

Key Hyperphosphatemia Market Questions:

  • What was the Hyperphosphatemia market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Hyperphosphatemia total market size as well as market size by therapies across the 7MM, China and Taiwan during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, China and Taiwan and which country will have the largest Hyperphosphatemia market size during the forecast period (2017-2030)?
  • At what CAGR, the Hyperphosphatemia market is expected to grow in 7MM, China and Taiwan during the forecast period (2017-2030)?
  • What would be the Hyperphosphatemia market outlook across the 7MM, China and Taiwan during the forecast period (2017-2030)?
  • What would be the Hyperphosphatemia market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/hyperphosphatemia-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Hyperphosphatemia

3. Competitive Intelligence Analysis for Hyperphosphatemia

4. Hyperphosphatemia: Market Overview at a Glance

5. Hyperphosphatemia: Disease Background and Overview

6. Patient Journey

7. Hyperphosphatemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Hyperphosphatemia Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Hyperphosphatemia: Seven Major Market, China and Taiwan Analysis

14. Attribute analysis

15. 7MM, China and Taiwan: Market Outlook

16. Access and Reimbursement Overview of Hyperphosphatemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hyperphosphatemia-market


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share